Regeneron Pharmaceuticals, Inc. $REGN Position Increased by LSV Asset Management

LSV Asset Management raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 199.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 166,514 shares of the biopharmaceutical company’s stock after buying an additional 110,914 shares during the period. LSV Asset Management’s holdings in Regeneron Pharmaceuticals were worth $128,527,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in REGN. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $226,000. Arrowstreet Capital Limited Partnership bought a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $3,183,000. Gabelli Funds LLC boosted its holdings in Regeneron Pharmaceuticals by 3.0% during the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after buying an additional 55 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in Regeneron Pharmaceuticals by 18.8% during the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after buying an additional 5,120 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported strong early results for Lynozyfic (linvoseltamab) in systemic AL amyloidosis, including rapid reductions in disease markers, a 100% complete response rate at the highest dose, and signs of improved heart and kidney function. The program remains investigational, but the data support a potential new growth opportunity. Article Title
• Positive Sentiment: Regeneron also announced that the European Medicines Agency accepted its filing for Otarmeni (lunsotogene parvec) in genetic hearing loss, a regulatory step that could expand the company’s rare-disease pipeline in the EU if approved. Article Title
• Neutral Sentiment: A Zacks piece highlighted REGN as a “strong value stock,” reflecting continued analyst support for the shares despite recent volatility. Article Title
• Negative Sentiment: Investor alerts and law-firm announcements said they are investigating possible securities claims against Regeneron after its Phase 3 melanoma trial for fianlimab plus Libtayo missed its primary endpoint versus Keytruda, raising legal and execution concerns. Article Title
• Negative Sentiment: Separate reports quoted Jim Cramer saying REGN could face more downgrades after the poor melanoma readout, reinforcing the market’s worry that the failed study may weigh on near-term sentiment. Article Title

Analyst Ratings Changes

A number of brokerages recently weighed in on REGN. Barclays reduced their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Canaccord Genuity Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ:REGN opened at $638.88 on Friday. The firm has a fifty day moving average of $731.45 and a two-hundred day moving average of $744.92. The firm has a market capitalization of $67.54 billion, a P/E ratio of 15.57, a price-to-earnings-growth ratio of 1.41 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter last year, the business posted $8.22 EPS. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.